# EpicentRx

Source: https://onco.cc/companies/epicentrx/  
OnCo record `epicentrx` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

EpicentRx is a United States-based biotechnology company running 3 late-stage cancer trials in sarcomas, head and neck squamous cell carcinoma and small-cell lung cancer.

## Summary

EpicentRx, based in La Jolla, the United States, is a biotechnology company. EpicentRx is a clinical-stage company developing therapies for inflammatory diseases and supportive care conditions, including an oncolytic virus immunotherapy and a small molecule for treatment-related toxicities. On ClinicalTrials.gov it is the lead sponsor of 3 recruiting or active phase 2 and phase 3 interventional cancer trials (1 in phase 3) in sarcomas, head and neck squamous cell carcinoma, small-cell lung cancer and non-small-cell lung cancer. The largest, NCT05566041 (A Phase 3, Controlled, Open-label, Global Randomised Study of RRx-001 With a Platinum Doublet or a Platinum Doublet in Small Cell Lung Cancer), plans to enrol 292 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: EpicentRx, Inc.
- Tags: ctgov-sponsor
- HQ: La Jolla
- Type: biotech
- Website: https://www.epicentrx.com

## Sources

- Official website: https://www.epicentrx.com
- ClinicalTrials.gov: trials led by EpicentRx: https://clinicaltrials.gov/search?lead=EpicentRx%2C%20Inc.

## Connected records

- cancers: [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Sarcomas (soft tissue, bone, GIST)](https://onco.cc/cancers/sarcoma/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- trials: [A Phase 3, Controlled, Open-label, Global Randomized Study of RRx-001 With a Platinum Doublet or a Platinum Doublet in Small Cell Lung Cancer](https://onco.cc/trials/nct05566041/), [A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors](https://onco.cc/trials/nct04673942/), [RRx-001 for Reducing Oral Mucositis in Patients Receiving Chemotherapy and Radiation for Head and Neck Cancer](https://onco.cc/trials/nct05966194/)

---
JSON: https://onco.cc/api/v1/entities/epicentrx.json